Primary Aldosteronism
Conditions
Keywords
Primary Aldosteronism, Spironolactone, Finerenone
Brief summary
To study the efficacy and safety of finerenone vs. spironolactone in patients with primary aldosteronism
Detailed description
1. Study design: This is a multi-center, double-blind, randomized, non-inferiority trial of finerenone vs. spironolactone in hypertensive patients with primary aldosteronism (PA). All patients will be randomized into finerenone group (Intervention group) and spironolactone group (Control group). 2. Objective: To compare the antihypertensive effects and Correction of hypokalemia in patients with PA. 3. Medicine: Finerenone (10mg tablet) and the matching placebo; Spironolactone (20mg tablet) and the matching placebo. 4. Study population: Men or women aged from18 years to 75 years old, with history of hypertension, Clinic DBP \<110 mmHg, SBP \<180 mmHg without any antihypertensive drugs for 2 weeks, were diagnosed PA and confirmed by captopril inhibition test or Saline infusion test. At the end of induction, Serum potassium level ≥ 3 mmol/L but less than 5 mmol/L. 5. Randomized and treatment: The initial dose of finerenone group is 10mg and spironolactone group is 20mg, respectively (week 0). For patients not meeting clinic blood pressure \< 140/90mmHg and the serum potassium ≥ 3.5 mmol/L, the dose of finerenone or spironolactone should be increased one tablet at every visit (week 2, week 4). The whole treatment period was 8 weeks. 6. Follow up: After the induction period of two weeks and meeting the inclusion criteria, the patients with primary aldosteronism were randomized in an equal ratio to receive finerenone 10mg once daily. Patients received the initial dose (10mg, week 0) of drug for the first two weeks of randomized treatments period. Thereafter, the dose of finernone would not be changed for the adequate blood pressure (BP) control and the normal serum potassium. For patients not meeting BP \< 140/90mmHg and the serum potassium ≥ 3.5 mmol/L, the dose of finerenone would be increased to 20mg once daily for the second 2 weeks later (week 2) and 30 mg 4 weeks later (week 4), respectively. The whole treatment period was 8 weeks. if blood pressure \> 160/110 mmHg during the clinical trial, amlodipine 5 mg once was added. At every visit, the clinic and ambulatory blood pressure will be measured. The levels of serum potassium, creatinine, renin, aldosterone will be examined. The urinary microalbumin creatinine ratio will be also examined. 7. Organization: The Centre for Epidemiological Studies and Clinical Trials, Department of Hypertension, Ruijin Hospital, Shanghai, China.
Interventions
DRUGFinerenone
At every visit, the clinic and ambulatory blood pressure will be measured. The levels of serum potassium, creatinine, renin, aldosterone will be examined. The urinary microalbumin creatinine ratio will be also examined.
DRUGSpironolactone
At every visit, the clinic and ambulatory blood pressure will be measured. The levels of serum potassium, creatinine, renin, aldosterone will be examined. The urinary microalbumin creatinine ratio will be also examined.
Sponsors
Shanghai Jiao Tong University School of Medicine
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Age: 18-75 years old. 2. History of hypertension, Clinic DBP \<110 mmHg, SBP \<180 mmHg without any antihypertensive drugs for 2 weeks. 3. Primary Aldosteronism diagnosed and confirmed by captopril inhibition test or Saline infusion test. 4. At the end of induction, Serum potassium level ≥ 3 mmol/L but less than 5 mmol/L. 5. Signed the informed consent
Exclusion criteria
1. Other kinds of secondary hypertension 2. Obesity with BMI\>30kg/m²（BMI= kg/㎡） 3. Serum potassium \> 5.5 mmol/L 4. Serious hypertension（msSBP≥180mmHg, and/or msDBP≥110mmHg） 5. Abnormal renal function: serum creatinine ≥ 2 × ULN or eGFR \< 25 ml/(min \* 1.73㎡); 6. Abnormal liver function: ALT and AST ≥ 2 × ULN； 7. Cardiac insufficiency, acute myocardial infarction, stroke or other acute cardiovascular events within 6 months; 8. Take spironolactone, guanethidine or reserpine 30 days before enrollment; 9. Known or suspected tumor; Other autoimmune diseases, uncontrolled infectious diseases, serious respiratory, blood and nervous system diseases; 10. There is a pregnancy plan in pregnancy or 3 months before and after treatment. Breast-feeding women; 11. Those who have mental illness, alcohol or drug abuse and cannot cooperate with treatment. 12. Be allergic to the study drugs 13. Without Signed the informed consent 14. Anticipating another clinical trial
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The proportion of patients with normal serum potassium level. | 8 weeks | serum potassium level |
| The change of 24-hour ambulatory systolic blood pressure from the baseline level. | 8 weeks | 24-hour ambulatory systolic blood pressure |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The change of other components of 24-hour ambulatory blood pressure from the baseline level. | 8 weeks | other components of 24-hour ambulatory blood pressure |
| The changes of plasma renin and aldosterone from the baseline levels. | 8 weeks | plasma renin and aldosterone |
| The change of estimate glomerular filtration rate from the baseline level. | 8 weeks | estimate glomerular filtration rate |
| The change of urinary microalbumin creatinine ratio (ACR) from the baseline level. | 8 weeks | urinary microalbumin creatinine ratio |
| The change of clinic systolic and diastolic blood pressure from the baseline level. | 8 weeks | clinic systolic and diastolic blood pressure |
Other
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Treatment-Adverse Events as assessed by gynaecomastia, mastodynia, menstrual abnormalities, impotence, hyperkalemia and other adverse events. | 8 weeks | gynaecomastia, mastodynia, menstrual abnormalities, impotence, hyperkalemia |
Countries
China
Contacts
Primary ContactJiguang Wang, MD. PhD
Backup ContactYuanyuan Kang, MD. PhD
Outcome results
None listed